Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells - PubMed (original) (raw)

Comparative Study

. 2007 Dec;24(12):2402-11.

doi: 10.1007/s11095-007-9425-y. Epub 2007 Sep 9.

Affiliations

• PMID: 17828616
• DOI: 10.1007/s11095-007-9425-y

Comparative Study

Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells

Tao Yang et al. Pharm Res. 2007 Dec.

Abstract

Purpose: The antitumor effect of paclitaxel-loaded PEGylated immunoliposome (PILs) was investigated in breast cancer cell lines and the xenograft model.

Methods: Herceptin was conjugated to paclitaxel-loaded PEGylated liposomes (PLs). In vitro cellular uptake and cytotoxicity of PILs were determined in breast cancer cell lines while in vivo antitumor efficacy was evaluated in the xenograft nude mouse model.

Results: The PILs formulation was able to significantly increase the HER2 mediated cellular uptake of paclitaxel compared to the PLs in cell lines overexpressing HER2 (BT-474 and SK-BR-3 cells). However, in the MDA-MB-231 cells, which express low levels of HER2, the difference between the PILs and PLs formulation was not significant. The biological activity of Herceptin was maintained throughout the conjugation process as exhibited by the antitumor dose-response curves determined for Herceptin itself, for the thiolated Herceptin alone and subsequently for the immunoliposome-coupled Herceptin. In BT-474 and SK-BR-3 cells, the cytotoxicity of the PILs was more potent than that of Taxol. Moreover, in in vivo studies, PILs showed significantly higher tumor tissue distribution of paclitaxel in the BT-474 xenograft model and more superior antitumor efficacy compared to Taxol and PLs. However, in the MDA-MB-231 xenograft model, PILs and PLs showed similar tumor tissue distribution as well as antitumor activity.

Conclusions: These results suggest that HER2-mediated endocytosis is involved in the PILs formulation. The ability of the PILs formulation to efficiently and specifically deliver paclitaxel to the HER2-overexpressing cancer cells implies that it is a promising strategy for tumor-specific therapy for HER2-overexpressing breast cancers.

PubMed Disclaimer

Similar articles

• Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome.
  Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD. Yang T, et al. J Control Release. 2007 Jul 31;120(3):169-77. doi: 10.1016/j.jconrel.2007.05.011. Epub 2007 May 17. J Control Release. 2007. PMID: 17586082
• Antibody-conjugated pH-sensitive liposomes for HER-2 positive breast cancer: development, characterization, in vitro and in vivo assessment.
  Raikwar S, Yadav V, Jain S, Jain SK. Raikwar S, et al. J Liposome Res. 2024 Jun;34(2):239-263. doi: 10.1080/08982104.2023.2248505. Epub 2023 Aug 28. J Liposome Res. 2024. PMID: 37594466
• Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.
  Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. Yang T, et al. Int J Pharm. 2007 Jun 29;338(1-2):317-26. doi: 10.1016/j.ijpharm.2007.02.011. Epub 2007 Feb 13. Int J Pharm. 2007. PMID: 17368984
• Interaction between Herceptin and taxanes.
  Diéras V, Beuzeboc P, Laurence V, Pierga JY, Pouillart P. Diéras V, et al. Oncology. 2001;61 Suppl 2:43-9. doi: 10.1159/000055401. Oncology. 2001. PMID: 11694787 Review.
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
  Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Sliwkowski MX, et al. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. Semin Oncol. 1999. PMID: 10482195 Review.

Cited by

• Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.
  Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R. Puri A, et al. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523-80. doi: 10.1615/critrevtherdrugcarriersyst.v26.i6.10. Crit Rev Ther Drug Carrier Syst. 2009. PMID: 20402623 Free PMC article. Review.
• The in vitro sub-cellular localization and in vivo efficacy of novel chitosan/GMO nanostructures containing paclitaxel.
  Trickler WJ, Nagvekar AA, Dash AK. Trickler WJ, et al. Pharm Res. 2009 Aug;26(8):1963-73. doi: 10.1007/s11095-009-9911-5. Epub 2009 May 20. Pharm Res. 2009. PMID: 19455409
• Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.
  Cai L, Wang X, Wang W, Qiu N, Wen J, Duan X, Li X, Chen X, Yang L, Qian Z, Wei Y, Chen L. Cai L, et al. Int J Nanomedicine. 2012;7:4499-510. doi: 10.2147/IJN.S32817. Epub 2012 Aug 14. Int J Nanomedicine. 2012. PMID: 22923988 Free PMC article.
• Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation.
  Ahmed M, Moussa M, Goldberg SN. Ahmed M, et al. Chem Phys Lipids. 2012 May;165(4):424-37. doi: 10.1016/j.chemphyslip.2011.12.002. Epub 2011 Dec 14. Chem Phys Lipids. 2012. PMID: 22197685 Free PMC article. Review.
• Development of recombinant cationic polymers for gene therapy research.
  Canine BF, Hatefi A. Canine BF, et al. Adv Drug Deliv Rev. 2010 Dec 30;62(15):1524-9. doi: 10.1016/j.addr.2010.04.001. Epub 2010 Apr 14. Adv Drug Deliv Rev. 2010. PMID: 20399239 Free PMC article. Review.

References

1. 1. Science. 1987 Jan 9;235(4785):177-82 - PubMed
2. 1. Int J Pharm. 2007 Jun 29;338(1-2):317-26 - PubMed
3. 1. Br J Cancer. 1987 Sep;56(3):279-85 - PubMed
4. 1. Nature. 1986 Jan 16-22;319(6050):230-4 - PubMed
5. 1. Breast Cancer Res Treat. 2005 Aug;92(3):251-63 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal